Dezima Pharma develops drugs to treat dyslipidemia, a major modifiable risk for cardiovascular disease. Its objective is to develop compounds from pre-clinical development to meaningful proof of concept in patients. Dezima will seek strategic partners to further development in the larger cardiovascular indications, and/or continue in-house development of its compounds in smaller, orphan-type indications. The Netherlands-based company was founded by Forbion Capital Partner and BioGeneration Ventures.

Dynamic Biosensors develops and commercializes the proprietary switchSENSE technology for molecular interaction analysis. In addition to binding affinity and kinetics, the dynamic character switchSENSE allows to determine molecular size, conformational changes, charge, and certain post-translational modifications of the target in the same measurement. Dynamic Biosensors is a spin-off of the Technische Universität München.